Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV study.
Corrected minute ventilation
Dead space
Lung ultrasound
Noninvasive ventilation
Ventilatory ratio
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
29 04 2022
29 04 2022
Historique:
received:
15
11
2021
accepted:
02
03
2022
entrez:
30
4
2022
pubmed:
1
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Whether prone position (PP) improves clinical outcomes in COVID-19 pneumonia treated with noninvasive ventilation (NIV) is unknown. We evaluated the effect of early PP on 28-day NIV failure, intubation and death in noninvasively ventilated patients with moderate-to-severe acute hypoxemic respiratory failure due to COVID-19 pneumonia and explored physiological mechanisms underlying treatment response. In this controlled non-randomized trial, 81 consecutive prospectively enrolled patients with COVID-19 pneumonia and moderate-to-severe (paO2/FiO2 ratio < 200) acute hypoxemic respiratory failure treated with early PP + NIV during Dec 2020-May 2021were compared with 162 consecutive patients with COVID-19 pneumonia matched for age, mortality risk, severity of illness and paO2/FiO2 ratio at admission, treated with conventional (supine) NIV during Apr 2020-Dec 2020 at HUMANITAS Gradenigo Subintensive Care Unit, after propensity score adjustment for multiple baseline and treatment-related variables to limit confounding. Lung ultrasonography (LUS) was performed at baseline and at day 5. Ventilatory parameters, physiological dead space indices (DSIs) and circulating inflammatory and procoagulative biomarkers were monitored during the initial 7 days. In the intention-to-treat analysis. NIV failure occurred in 14 (17%) of PP patients versus 70 (43%) of controls [HR = 0.32, 95% CI 0.21-0.50; p < 0.0001]; intubation in 8 (11%) of PP patients versus 44 (30%) of controls [HR = 0.31, 95% CI 0.18-0.55; p = 0.0012], death in 10 (12%) of PP patients versus 59 (36%) of controls [HR = 0.27, 95% CI 0.17-0.44; p < 0.0001]. The effect remained significant within different categories of severity of hypoxemia (paO2/FiO2 < 100 or paO2/FiO2 100-199 at admission). Adverse events were rare and evenly distributed. Compared with controls, PP therapy was associated with improved oxygenation and DSIs, reduced global LUS severity indices largely through enhanced reaeration of dorso-lateral lung regions, and an earlier decline in inflammatory markers and D-dimer. In multivariate analysis, day 1 CO2 response outperformed O2 response as a predictor of LUS changes, NIV failure, intubation and death. Early prolonged PP is safe and is associated with lower NIV failure, intubation and death rates in noninvasively ventilated patients with COVID-19-related moderate-to-severe hypoxemic respiratory failure. Early dead space reduction and reaeration of dorso-lateral lung regions predicted clinical outcomes in our study population. ISRCTN23016116 . Retrospectively registered on May 1, 2021.
Sections du résumé
BACKGROUND
Whether prone position (PP) improves clinical outcomes in COVID-19 pneumonia treated with noninvasive ventilation (NIV) is unknown. We evaluated the effect of early PP on 28-day NIV failure, intubation and death in noninvasively ventilated patients with moderate-to-severe acute hypoxemic respiratory failure due to COVID-19 pneumonia and explored physiological mechanisms underlying treatment response.
METHODS
In this controlled non-randomized trial, 81 consecutive prospectively enrolled patients with COVID-19 pneumonia and moderate-to-severe (paO2/FiO2 ratio < 200) acute hypoxemic respiratory failure treated with early PP + NIV during Dec 2020-May 2021were compared with 162 consecutive patients with COVID-19 pneumonia matched for age, mortality risk, severity of illness and paO2/FiO2 ratio at admission, treated with conventional (supine) NIV during Apr 2020-Dec 2020 at HUMANITAS Gradenigo Subintensive Care Unit, after propensity score adjustment for multiple baseline and treatment-related variables to limit confounding. Lung ultrasonography (LUS) was performed at baseline and at day 5. Ventilatory parameters, physiological dead space indices (DSIs) and circulating inflammatory and procoagulative biomarkers were monitored during the initial 7 days.
RESULTS
In the intention-to-treat analysis. NIV failure occurred in 14 (17%) of PP patients versus 70 (43%) of controls [HR = 0.32, 95% CI 0.21-0.50; p < 0.0001]; intubation in 8 (11%) of PP patients versus 44 (30%) of controls [HR = 0.31, 95% CI 0.18-0.55; p = 0.0012], death in 10 (12%) of PP patients versus 59 (36%) of controls [HR = 0.27, 95% CI 0.17-0.44; p < 0.0001]. The effect remained significant within different categories of severity of hypoxemia (paO2/FiO2 < 100 or paO2/FiO2 100-199 at admission). Adverse events were rare and evenly distributed. Compared with controls, PP therapy was associated with improved oxygenation and DSIs, reduced global LUS severity indices largely through enhanced reaeration of dorso-lateral lung regions, and an earlier decline in inflammatory markers and D-dimer. In multivariate analysis, day 1 CO2 response outperformed O2 response as a predictor of LUS changes, NIV failure, intubation and death.
CONCLUSION
Early prolonged PP is safe and is associated with lower NIV failure, intubation and death rates in noninvasively ventilated patients with COVID-19-related moderate-to-severe hypoxemic respiratory failure. Early dead space reduction and reaeration of dorso-lateral lung regions predicted clinical outcomes in our study population.
CLINICAL TRIAL REGISTRATION
ISRCTN23016116 . Retrospectively registered on May 1, 2021.
Identifiants
pubmed: 35488356
doi: 10.1186/s13054-022-03937-x
pii: 10.1186/s13054-022-03937-x
pmc: PMC9052189
doi:
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Informations de copyright
© 2022. The Author(s).
Références
BMJ. 1990 Jan 27;300(6719):230-5
pubmed: 2106931
Lancet Respir Med. 2021 May;9(5):e47-e48
pubmed: 33684356
Crit Care Med. 2021 Oct 1;49(10):e1015-e1024
pubmed: 33938714
JAMA. 2016 Jun 14;315(22):2435-41
pubmed: 27179847
Lancet Respir Med. 2021 Dec;9(12):1387-1395
pubmed: 34425070
Crit Care. 2021 Sep 17;25(1):339
pubmed: 34535169
Crit Care. 2021 Sep 13;25(1):331
pubmed: 34517881
Crit Care Med. 2000 Feb;28(2):295-303
pubmed: 10708156
Crit Care. 2021 Jun 14;25(1):209
pubmed: 34127046
J Infect. 2021 Feb;82(2):e5-e7
pubmed: 32998036
Am J Respir Crit Care Med. 2000 Jun;161(6):2005-12
pubmed: 10852781
Am J Respir Crit Care Med. 2013 Dec 15;188(12):1428-33
pubmed: 24102072
Anesthesiology. 2010 Mar;112(3):682-7
pubmed: 20179506
Int J Med Sci. 2021 Jan 11;18(5):1198-1206
pubmed: 33526981
Respir Care. 2021 Apr;66(4):619-625
pubmed: 33293365
Crit Care. 2021 Sep 17;25(1):340
pubmed: 34535158
Crit Care. 2020 Jul 6;24(1):394
pubmed: 32631393
JAMA. 2021 May 4;325(17):1731-1743
pubmed: 33764378
Medicine (Baltimore). 2020 Oct 16;99(42):e22433
pubmed: 33080676
Front Med (Lausanne). 2020 Dec 23;7:614152
pubmed: 33425957
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Crit Care. 2013 Feb 27;17(1):R34
pubmed: 23445563
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Intensive Care Med. 2011 Feb;37(2):257-62
pubmed: 21063677
Am J Trop Med Hyg. 2021 Mar 11;104(5):1676-1686
pubmed: 33705348
Crit Care. 2022 Jan 4;26(1):12
pubmed: 34983597
Lancet Respir Med. 2020 Aug;8(8):765-774
pubmed: 32569585
ERJ Open Res. 2021 Jan 25;7(1):
pubmed: 33527074
Semin Respir Crit Care Med. 2019 Feb;40(1):94-100
pubmed: 31060091
Ann Am Thorac Soc. 2021 Jun;18(6):1020-1026
pubmed: 33395553
Crit Care. 2021 Jan 25;25(1):35
pubmed: 33494771
Am J Respir Crit Care Med. 2020 Sep 1;202(5):690-699
pubmed: 32667207
Ultrasound Med Biol. 2020 Nov;46(11):2918-2926
pubmed: 32771222
J Crit Care. 2021 Feb;61:63-70
pubmed: 33096347
Crit Care. 2014 May 28;18(3):R109
pubmed: 24887034
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:69-80
pubmed: 22552982
Crit Care. 2021 Apr 6;25(1):128
pubmed: 33823862
Crit Care Med. 2018 Nov;46(11):1761-1768
pubmed: 30048331
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Minerva Anestesiol. 2021 Jun;87(6):740-744
pubmed: 33591145
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1644-55
pubmed: 9817720
Respir Care. 2009 Jan;54(1):71-84
pubmed: 19111108
Crit Care Med. 2016 Feb;44(2):282-90
pubmed: 26584191
N Engl J Med. 1998 Aug 13;339(7):429-35
pubmed: 9700176
Am J Respir Crit Care Med. 2011 Feb 1;183(3):341-7
pubmed: 20851923
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855